
    
      A double-blind, placebo controlled, randomised, parallel group phase IIa study to investigate
      the efficacy, tolerability, and safety of different dosing regimens of AZD8848 administered
      intranasally to seasonal allergic rhinitis patients out of pollen season in a nasal allergen
      challenge model
    
  